Search research articles
Contact Us
Filters
Showing results (21-30 of 24) with videos related to
Page
of 3
Sort By:
You have reached the last page of results.
This site can display upto 24 results.
European Journal of Cancer (Oxford, England : 1990)
|
June 24, 2018
Treatment strategies and outcomes in diffuse large B-cell lymphoma among 1011 patients aged 75 years or older: A Danish population-based cohort study
Maja Bech Juul, Pernille Hammershoej Jensen, Henriette Engberg, et al.
Journal of Fungi (Basel, Switzerland)
|
November 11, 2020
Introduction of a Comprehensive Diagnostic and Interdisciplinary Management Approach in Haematological Patients with Mucormycosis: A Pre and Post-Intervention Analysis
Malene Risum, Jannik Helweg-Larsen, Søren Lykke Petersen, et al.
Hemasphere
|
May 13, 2025
Biomarker-adapted treatment in high-risk large B-cell lymphoma
Sirpa Leppä, Leo Meriranta, Maare Arffman, et al.
Blood Advances
|
May 8, 2020
Patients with high-risk DLBCL benefit from dose-dense immunochemotherapy combined with early systemic CNS prophylaxis
Sirpa Leppä, Judit Jørgensen, Anne Tierens, et al.
Page
of 3
Search research articles
Search
Showing results (21-30 of 24) with videos related to
Sort By:
Page
of 3
You have reached the last page of results.
This site can display upto 24 results.
European Journal of Cancer (Oxford, England : 1990)
|
June 24, 2018
Treatment strategies and outcomes in diffuse large B-cell lymphoma among 1011 patients aged 75 years or older: A Danish population-based cohort study
Maja Bech Juul, Pernille Hammershoej Jensen, Henriette Engberg, et al.
Journal of Fungi (Basel, Switzerland)
|
November 11, 2020
Introduction of a Comprehensive Diagnostic and Interdisciplinary Management Approach in Haematological Patients with Mucormycosis: A Pre and Post-Intervention Analysis
Malene Risum, Jannik Helweg-Larsen, Søren Lykke Petersen, et al.
Hemasphere
|
May 13, 2025
Biomarker-adapted treatment in high-risk large B-cell lymphoma
Sirpa Leppä, Leo Meriranta, Maare Arffman, et al.
Blood Advances
|
May 8, 2020
Patients with high-risk DLBCL benefit from dose-dense immunochemotherapy combined with early systemic CNS prophylaxis
Sirpa Leppä, Judit Jørgensen, Anne Tierens, et al.
Page
of 3